Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorigerlimab - MacroGenics

Drug Profile

Lorigerlimab - MacroGenics

Alternative Names: AEX1344; EXPASY; MGD-019; PD-1 x CTLA-4 bispecific DART molecule

Latest Information Update: 16 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 06 Nov 2023 Macrogenics plans a phase I/II trial for Solid tumours (Combination therapy) in USA in 2024
  • 28 Sep 2023 Phase-II clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory) in United Kingdom, Spain, Puerto Rico, Poland, Georgia, France, Bulgaria, Belgium, USA (IV) (NCT05848011)
  • 28 May 2023 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Bulgaria (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top